Antimicrobials
Voriconazole

Voriconazole

Low
Excellent

Spectrum of Activity

Dosing

General Information

Primary indication(s): Invasive Aspergillus infections (including CNS aspergillosis)

Candida infections both mucocutaneous and invasive - i.e. Candidemia.

Antifungal prophylaxis in immunocompromised patients.

Therapeutic drug monitoring recommended to ensure adequate concentrations and exclude toxicity (Discuss with ID). -Target 1 – 5.5 μg/mL, 5-7 days after starting therapy

QTc interval in patients at elevated risk.

Monitor hepatic profile.

  • Drug interactions
  • QTc prolongation
  • Hepatic enzyme abnormalities
  • Rash - up to 20%
  • Visual disturbance
  • Fluorosis - GI upset

CYP450 interactions ++

Other QTc prolonging agents

Recommend review of pt medications due to high frequency of significant interactions

Antimicrobial class: Triazole antifungal, Second generation

Pregnancy category: D

Urine penetration: Poor

Lung penetration: Therapeutic

CSF penetration: Therapeutic